LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

Home・Stock List・Incyte Corp
Search

Incyte Corp

Open

SectorHealthcare

96.88 -0.15

Buy

Price update 26 May 2026, 16:14 UTC

BuySell

Overview

Share price change

24h

Current

Min

96.01

Max

97.89

Key metrics

By Trading Economics

Income

4.1M

303M

Sales

-234M

1.3B

P/E

Sector Avg

13.445

49.701

EPS

1.81

Profit margin

23.834

Employees

2,844

EBITDA

-47M

367M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+11.46% upside

Dividends

By Dow Jones

Next Earnings

28 Jul 2026

Market Stats

By TradingEconomics

Market Cap

-31M

19B

Previous open

97.03

Previous close

96.88

News Sentiment

By Acuity

43%

57%

131 / 345 Healthcare

Incyte Corp Chart

Past performance is not a reliable indicator of future results.

Related News

25 May 2026, 08:24 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

DJ

Read

25 May 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

DJ

Read

25 May 2026, 20:50 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

DJ

Read

25 May 2026, 16:20 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

DJ

Read

25 May 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

DJ

Read

25 May 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

DJ

Read

25 May 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

DJ

Read

25 May 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Read

25 May 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

DJ

Read

25 May 2026, 12:56 UTC

Market Talk
Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

DJ

Read

25 May 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

DJ

Read

25 May 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

25 May 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

DJ

Read

25 May 2026, 12:10 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

DJ

Read

25 May 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

DJ

Read

25 May 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

DJ

Read

25 May 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

DJ

Read

25 May 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

DJ

Read

25 May 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

DJ

Read

25 May 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

DJ

Read

25 May 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

DJ

Read

25 May 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

DJ

Read

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

DJ

Read

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

DJ

Read

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

DJ

Read

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

DJ

Read

25 May 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

DJ

Read

25 May 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

25 May 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

DJ

Read

25 May 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

DJ

Read

Peer Comparison

Price change

Incyte Corp Forecast

Price Target

By TipRanks

11.46% upside

12 Months Forecast

Average 108.29 USD  11.46%

High 135 USD

Low 75 USD

Based on 19 Wall Street analysts offering 12 month price targets forIncyte Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

8

Buy

10

Hold

1

Sell

Based on 19 analysts giving stock ratings to Incyte Corp - Dist in the past 3 months.

Sentiment

By Acuity

131 / 345 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Other stocks from the sector

LLY

Eli Lilly and Co.

1,078.15

↑ +1.06%

JNJ

Johnson and Johnson

230.66

↓-1.67%

ABBV

AbbVie Inc

214.25

↓-0.87%

UNH

UnitedHealth Group Inc

378.22

↓-2.56%

AZN

AstraZeneca PLC

188.44

↑ +0.64%
help-icon Live chat